Breast Tissue Markers Market Report 2024

This Breast Tissue Markers market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The breast tissue markers market size has grown strongly in recent years. It will grow from $2.54 billion in 2023 to $2.75 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be attributed to advancements in imaging technology, an increase in breast cancer screening programs, the development of minimally invasive biopsy techniques, regulatory approvals and standardization, and preferences of surgeons and radiologists.

The breast tissue markers market size is expected to see strong growth in the next few years. It will grow to $3.79 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The growth expected during the forecast period can be attributed to the increasing adoption of personalized medicine, higher demand for minimally invasive procedures, expansion of outpatient and ambulatory surgical centers, rising healthcare expenditures and insurance coverage, and the integration of artificial intelligence. Key trends for this period include a growing use of biodegradable breast tissue markers, integration with advanced imaging technologies, a focus on patient comfort, sustainability, and eco-friendly products, collaboration between diagnostic and therapeutic systems, and the adoption of wireless and remote monitoring.

The increasing incidence of breast cancer is expected to drive the growth of the breast tissue markers market. Breast cancer, a malignant tumor originating in the breast tissue, is on the rise due to factors such as extended life expectancy, advancements in detection methods, lifestyle changes, and environmental influences. Breast tissue markers play a crucial role in diagnosing, monitoring disease progression, and guiding treatment by detecting specific proteins or genetic mutations. According to the American Cancer Society, the number of new invasive breast cancer cases in women in the US increased from approximately 281,550 in 2021 to 297,790 in 2023. Similarly, cases among men rose from 2,650 to 2,800 during the same period. This upward trend in breast cancer cases is driving the growth of the breast tissue markers market.

Key players in the breast tissue markers market are innovating with new solutions, such as breast biopsy site markers, to enhance ultrasound visibility, facilitate location, and reduce displacement during surgical procedures. A breast biopsy site marker is a small device used to mark the biopsy site for future imaging or surgical procedures. For example, in August 2023, Mammotome, a US-based provider of breast biopsy markers, launched the HydroMARK Plus breast biopsy site marker. This marker features a hydrogel design that expands upon contact with fluid, improving visibility in ultrasound imaging. Its innovative design ensures precise site marking and accurate localization for subsequent diagnostic and treatment procedures, while offering long-term stability within breast tissue and minimizing the need for additional interventions.

In July 2024, Hologic Inc., a US-based health technology company, acquired Endomagnetics Ltd. for an undisclosed amount. This acquisition enables Hologic to enhance its breast cancer diagnostics and treatment capabilities by incorporating Endomagnetics' advanced magnetic detection technologies. Endomagnetics Ltd., a UK-based provider of breast tissue markers, will contribute to Hologic's expanded offerings in this domain.

Major companies operating in the breast tissue markers market are Johnson & Johnson Company, Thermo Fisher Scientific, Medtronic PLC, Siemens Healthineers, Stryker Corporation, GE HealthCare Technologies Inc., Hologic Inc., Kaiser Permanente, Cook Medical Inc., Merit Medical Systems Inc., Leica Biosystems Inc., Argon Medical Devices Inc., Devicor Medical Products Inc., Mermaid Medical Group, iCAD Inc., Endomag, Focal Therapeutics Inc., Laurane Medical, Carbon Medical Technologies Inc., Becton Dickinson and Company, INRAD Inc., Izi Medical Products LLC, Sanarus Technologies Inc., Scion Medical Technologies LLC, Biopsy Sciences LLC.

North America was the largest region in the breast tissue markers market in 2023. The regions covered in the breast tissue markers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the breast tissue markers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Breast tissue markers are small, implantable devices used in the diagnosis and treatment of breast cancer to indicate the location of a biopsy site, tumor, or area of concern within the breast tissue. These markers are usually inserted during a biopsy procedure to ensure precise identification of the site for future imaging, surgery, or treatment.

The main types of breast tissue markers are metal and non-metal. Metal breast tissue markers are made from materials such as stainless steel and are used to accurately identify and monitor breast tumors. These markers can be either non-biodegradable or partially biodegradable and come in various shapes, including coil, ribbon, butterfly, and v-shape, among others. They are used by a range of end-users, including hospitals, ambulatory surgical centers, diagnostic centers, and specialty clinics.

The breast tissue markers market research report is one of a series of new reports that provides breast tissue markers market statistics, including breast tissue markers industry global market size, regional shares, competitors with a breast tissue markers market share, detailed breast tissue markers market segments, market trends and opportunities, and any further data you may need to thrive in the breast tissue markers industry. This breast tissue markers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast tissue markers consist of sales of radiofrequency identification (RFID) markers, magnetic markers, ultrasound-visible markers, and hydrogel markers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.